Prepare Yourself for Liftoff: Seres Therapeutics Inc (MCRB)

With 0.91 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.12 million shares. The 52-week range on MCRB shows that it touched its highest point at $1.53 and its lowest point at $0.54 during that stretch. It currently has a 1-year price target of $3.31. Beta for the stock currently stands at 2.15.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MCRB was down-trending over the past week, with a drop of -4.33%, but this was down by -11.85% over a month. Three-month performance surged to 38.80% while six-month performance fell -6.69%. The stock lost -22.74% in the past year, while it has lost -3.31% so far this year. A look at the trailing 12-month EPS for MCRB yields -1.19 with Next year EPS estimates of -0.33. For the next quarter, that number is -0.20. This implies an EPS growth rate of 86.52% for this year and -175.37% for next year. EPS is expected to grow by 25.41% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 18.22%.

Float and Shares Shorts:

At present, 170.20 million MCRB shares are outstanding with a float of 124.86 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MCRB since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.02840921 being high and -$0.29672 being low. For MCRB, this leads to a yearly average estimate of -$0.11995. Based on analyst estimates, the high estimate for the next quarter is -$0.12 and the low estimate is -$0.26. The average estimate for the next quarter is thus -$0.19.